GKOS — Glaukos Corporation price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $245.72
- YTD price return
- +117.62%
- YTD total return
- +117.62%
- Market cap
- 14.5B
- Enterprise value
- 14.5B
- Shares outstanding
- 59.2M
- 52W low
- $87.32
- 52W high
- $255.19
- From 52W high
- -3.71%
- From 52W low
- +181.40%
- 52W range
- 94%$87.32–$255
- Beta
- 0.75
Volume
- Rel volume
- 0.33×
- 30D volume
- 1.6M
- 30D $ vol
- 344.5M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- −$11.3M
- Insider net 3M
- −$15.0M
- Insider net 1Y
- −$78.3M
Form 4 transactions by trade date, as filed; latest on file 2026-11-04.
Fundamentals
- Sales (ttm)
- 690.3M
- Sales/share
- $11.66
- EPS (ttm)
- -$2.88
- FCF (ttm)
- 36M
- FCF/share
- $0.61
- Book value/share
- $12.12
- Net margin
- -24.60%
- ROE
- -23.67%
- ROA
- -17.33%
- Current ratio
- 4.57
Growth (CAGR, ttm) · 10Y
- Sales
- +46.97%+31.49%+18.62%+21.14%
- FCF
- n/an/an/a+25.06%
- Shares
- +3.07%+6.65%+4.77%+5.84%
Per-share growth (CAGR, ttm) · 10Y
- Sales/share
- +42.60%+23.30%+13.22%+14.45%
- FCF/share
- n/an/an/a+18.16%
- Book value/share
- -9.57%+7.37%-1.12%+13.94%
- Price
- +167.82%+56.99%+37.10%+21.86%
- Total return
- +167.82%+56.99%+37.10%+21.86%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- -85.2×
- Fwd P/E
- 175.5×
- P/S (ttm)
- 21.1×
- P/B (mrq)
- 20.3×
- P/FCF (ttm)
- 403.8×
- EV/Sales (ttm)
- 21.0×
- FCF yield (ttm)
- 0.25%
- Buyback yield (realized, 1y)
- -3.07%
- Shareholder yield (realized, 1y)
- -3.07%
- Buyback yield (cash, ttm)
- 0.00%
- Shareholder yield (cash, ttm)
- 0.00%
Vs own 10Y history
- P/S
- 97th
- P/B
- 100th
- P/FCF
- 100th
Bar = where today’s multiple sits in GKOS’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-13#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y n/m10Y n/mYoY n/mEPS (diluted)
5Y n/m10Y n/mYoY n/mFree cash flow
5Y n/m10Y n/mYoY n/mTTM: operating cash flow $47.7M, capex −$11.7M
Q3 2026: operating cash flow $38.6M, capex −$2.1M
Shares (diluted)
5Y +28.5%10Y +227.3%YoY +6.6%Net income
5Y n/m10Y n/mYoY n/mAbout Glaukos#
Data provided bySource: Twelve DataGlaukos Corp. is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for glaucoma, corneal disorders, and retinal diseases. Its product portfolio includes Micro-Invasive Glaucoma Surgery (MIGS) devices, sustained-release drug delivery systems, and bio-activated therapies designed to address chronic eye disease across multiple stages of care. The company serves ophthalmologists, surgeons, and healthcare providers with solutions intended to improve treatment options in both surgical and pharmaceutical settings. Glaukos Corp. is a specialized participant in the eye care market, combining medical devices and medicines to support procedures and therapies used in glaucoma management and corneal health.
Aliso Viejo, CA·995 employees·Medical Devices·glaukos.com·As of Oct 28, 2026
Recent filings#
- Nov 4Insider sale · Kliman Gilbert H (Director) sold 5,000 shares for $1.1M on 2 days since Aug 19
- Oct 30Insider sale · Navratil Tomas (CHIEF DEVELOPMENT OFFICER) sold 58,180 shares for $13.1M on 2 days since Aug 28
- Oct 28Earnings · Earnings release — EPS $0.47 vs −$0.12 est. (+491.7%); revenue $211.0M (+58% y/y) 33.6%
- Aug 11Insider sale · Gilliam Joseph E (PRESIDENT & COO) sold 60,000 shares for $10.8M at $178.89–$180.49
- Jul 31Insider sale · WEN LEANA (Director) sold 525 shares for $88K at $167.63
ETFs holding GKOS#
15 of the 193 ETFs ChartRow carries live hold GKOS. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| VIOO | Vanguard S&P Small-Cap 600 ETF | 0.6% |
| IWO | iShares Russell 2000 Growth ETF | 0.5% |
| IJR | iShares Core S&P Small-Cap ETF | 0.4% |
| VTWO | Vanguard Russell 2000 ETF | 0.3% |
| IWM | iShares Russell 2000 ETF | 0.2% |
| VBK | Vanguard Small-Cap Growth ETF | 0.2% |
| VHT | Vanguard Health Care ETF | 0.1% |
| VXF | Vanguard Extended Market ETF | 0.1% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +23.75% | +1.14% |
| JNJ | Johnson & Johnson | +14.94% | +0.79% |
| ABBV | AbbVie Inc. | +7.53% | +0.20% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +7.86% | +0.58% |
| MRK | Merck & Co. Inc. | +4.07% | +0.55% |
| NVS | Novartis AG | +12.70% | +0.16% |
| TMO | Thermo Fisher Scientific Inc. | +5.61% | +0.11% |
| AMGN | Amgen Inc. | +12.80% | -0.30% |
